Sequenom, Inc. 

(Public, NASDAQ:SQNM)   Watch this stock   
Find more results for SQNM
Nov 9, 2009
Q3 2009 Conference Call
Nov 9, 2009
Q3 2009 Release
More events from AOL Finance »    

Key stats and ratios

Q2 (Jun '09) 2008
Net profit margin -220.83% -93.65%
Operating margin -221.60% -90.42%
EBITD margin - -84.27%
Return on average assets -66.61% -40.78%
Return on average equity -84.76% -51.80%
Employees 248 -

Address

3595 John Hopkins Court
San Diego, CA 92121
United States - Map
+1-858-2029000 (Phone)
+1-858-2029001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

Sequenom, Inc. discussed on blogs

Ranking 1100+ Micro Cap Stocks by Upside Potential - NASD100.com ... - Investor's Resources - NASD100.com - Daily Stock Rankings - Nov 20, 2009

Sequenom, Inc. discussions

  View all discussions »

Description

Sequenom, Inc. (Sequenom) is a diagnostic testing and genetics analysis company. The Company is focused on providing products, services, diagnostic testing, applications and genetic analysis products that translate the results of genomic science into solutions for biomedical research, translational research, molecular medicine applications, and agricultural, livestock and other areas of research. Its development and commercialization efforts in various diagnostic areas include non-invasive prenatal diagnostics, oncology, infectious diseases and other disorders. The Company is researching, developing and pursuing the commercialization of various non-invasive molecular diagnostic tests for prenatal genetic disorders and diseases, oncology, infectious diseases, and other diseases and disorders. On November 14, 2008, it completed the asset acquisition of the Center for Molecular Medicine, LLC (CMM). On November 17, 2008, the Company acquired Grand Rapids, a center for molecular medicine.

Officers and directors

Harry F. Hixson Jr., Ph.D.
Chairman of the Board, Interim Chief Executive Officer
Age: 71
Bio & Compensation - Reuters
Paul V. Maier
Interim Chief Financial Officer
Age: 61
Bio & Compensation - Reuters
Michael Monko
Senior Vice President - Sales and Marketing
Age: 49
Bio & Compensation - Reuters
Ronald M. Lindsay Ph.D.
Interim Senior Vice President - Research and Development, Director
Age: 61
Bio & Compensation - Reuters
Larry Myres
Vice President - Operations
Age: 50
Bio & Compensation - Reuters
Mary Rose Keller
Vice President - Clinical Operations
Bio & Compensation - Reuters
Clarke Neumann J.D.
Vice President, General Counsel, Assistant Secretary
Age: 45
Bio & Compensation - Reuters
Gary Riordan
Vice President - Regulatory Affairs & Quality
Age: 50
Bio & Compensation - Reuters
Joseph Zimmerman
Vice President - Managed Care
Bio & Compensation - Reuters
Karsten Schmidt Ph.D.
Vice President - Business Development
Age: 47
Bio & Compensation - Reuters